Search clinical trials for: Candonilimab（AK104）

Total 197 results

Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chongqing University Cancer Hospital
Akeso Pharmaceuticals, Inc.

Recruiting

Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
Shengjing Hospital

Not yet recruiting

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
West China Second University Hospital
The Affiliated Hospital Of Southwest Medical University; Afﬁliated Hospital...

Recruiting

A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer

Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
Akeso

Recruiting

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

Bladder Cancer

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Resectable Esophageal Squamous Cell Carcinoma
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University

Not yet recruiting

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University

Recruiting

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Hepatocellular Carcinoma Non-resectable | Immune Checkpoint Inhibitors | Portal Vein Tumor Thrombus

China
Cancer Institute and Hospital, Chinese Academy...
Akesobio

Not yet recruiting

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Pleural Mesothelioma
Peking University Third Hospital

Not yet recruiting

AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer

Cervical Cancer
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
Sun Yat-sen University
Akeso; Haplox Biotechnology Co., Ltd.

Recruiting

Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Guangxi Medical University

Not yet recruiting

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Immune Checkpoint Inhibitors
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Gastric Cancer | Esophagogastric Junction Cancer

China
Zhongnan Hospital
Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
Peking Union Medical College Hospital

Recruiting

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Cadonilimab and Lenvatinib

China
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Xuekui Liu

Recruiting

Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma (NCCCNRHNSCC)

Head and Neck Squamous Cell Carcinoma | Locally Advanced Operable

China
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Hunan Cancer Hospital

Recruiting

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
West China Hospital

Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Gastric Cancer
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Akeso

Not yet recruiting

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Vulvar Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Soft Tissue Sarcoma

China
Akeso

Not yet recruiting

AK104 in Neoadjuvant Treatment of Cervical Cancer

Cervical Cancer

China
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
The First Hospital of Jilin University

Not yet recruiting

Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

Lung Cancer
Peking University Cancer Hospital & Institute

Not yet recruiting

Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma
Qian Chu
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS)

Carcinoma, Non-Small-Cell Lung

China
Henan Cancer Hospital

Recruiting

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Fujian Cancer Hospital
The First Affiliated Hospital of Nanchang University; Fujian Provincial Hospital and other collaborators

Not yet recruiting

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma
Sun Yat-sen University

Not yet recruiting

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma

China
Chinese PLA General Hospital

Not yet recruiting

A Study of Combination Therapy in NSCLC

Non-small Cell Lung Cancer
Sun Yat-sen University

Recruiting

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006) (EC-CRT-006)

Esophagus Cancer

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Wuhan Union Hospital, China
Xiangya Hospital of Central South University; Sun Yat-sen University; The Affiliated... and other collaborators

Not yet recruiting

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Advanced Soft-tissue Sarcoma
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Search clinical trials for: Candonilimab（AK104）

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations